HUP0203269A2 - Method for the detection of mammalian carcinomas - Google Patents
Method for the detection of mammalian carcinomasInfo
- Publication number
- HUP0203269A2 HUP0203269A2 HU0203269A HUP0203269A HUP0203269A2 HU P0203269 A2 HUP0203269 A2 HU P0203269A2 HU 0203269 A HU0203269 A HU 0203269A HU P0203269 A HUP0203269 A HU P0203269A HU P0203269 A2 HUP0203269 A2 HU P0203269A2
- Authority
- HU
- Hungary
- Prior art keywords
- spatial distribution
- sample
- detection
- component
- specific component
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 5
- 201000009030 Carcinoma Diseases 0.000 title abstract 2
- 238000001514 detection method Methods 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 239000013074 reference sample Substances 0.000 abstract 2
- 239000000523 sample Substances 0.000 abstract 2
- 230000009466 transformation Effects 0.000 abstract 2
- 208000035269 cancer or benign tumor Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 210000003855 cell nucleus Anatomy 0.000 abstract 1
- 238000012512 characterization method Methods 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 210000004962 mammalian cell Anatomy 0.000 abstract 1
- 210000004940 nucleus Anatomy 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
A találmány eljárást ismertet sejtproliferációs rendellenességkimutatására egy egyénben, amely egy emlős sejtmag specifikusalkotórészének, vagyis proteineknek és más molekuláknak a térbelieloszlásán alapul és amely lehetővé teszi annak megállapítását, hogyvajon a sejt normál állapotban van-e, vagy pedig tumoros állapotbavaló transzformáción ment keresztül. Amennyiben transzformációtörtént, a térbeli eloszlás lehetővé teszi ennek kimutatását és atumor minősítését. Az eljárás a következőket tartalmazza: a) azemlített analizálandó egyénből származó mintában lévő sejtmag legalábbegy specifikus alkotórésze térbeli eloszlásának meghatározását; b) azemlített térbeli eloszlás egy referenciaminta legalábbis egyspecifikus azonos alkotórészének térbeli eloszlásával valóösszehasonlítását; és c) az említett minta említett legalább egyspecifikus alkotórészének jellemzését az említett referenciamintalegalább egy azonos alkotórészével való összehasonlítás alapján. Azeljárás jól használható proliferációs rendellenességek, főkéntkarcinómák diagnosztikájában, (korai) kimutatásra szolgáló eredményesmódszerként. ÓThe invention describes a method for detecting a cell proliferation disorder in an individual, which is based on the spatial distribution of a specific component of a mammalian cell nucleus, i.e. proteins and other molecules, and which makes it possible to determine whether the cell is in a normal state or has undergone transformation into a tumor state. If a transformation has occurred, the spatial distribution enables it to be detected and classified as a tumor. The procedure includes the following: a) determination of the spatial distribution of at least one specific component of the cell nucleus in the sample from the individual to be analyzed; b) comparing the above spatial distribution with the spatial distribution of at least one specific identical component of a reference sample; and c) characterization of said at least one specific component of said sample based on comparison with at least one identical component of said reference sample. The method can be used well in the diagnosis of proliferative disorders, especially carcinomas, as an effective method for (early) detection. HE
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99203582 | 1999-11-01 | ||
| PCT/EP2000/011050 WO2001033229A1 (en) | 1999-11-01 | 2000-11-01 | Method for the detection of mammalian carcinomas |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUP0203269A2 true HUP0203269A2 (en) | 2003-02-28 |
Family
ID=8240801
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0203269A HUP0203269A2 (en) | 1999-11-01 | 2000-11-01 | Method for the detection of mammalian carcinomas |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1226439A1 (en) |
| JP (1) | JP2003513282A (en) |
| AU (1) | AU2156501A (en) |
| CA (1) | CA2389364A1 (en) |
| HU (1) | HUP0203269A2 (en) |
| NZ (1) | NZ519065A (en) |
| WO (1) | WO2001033229A1 (en) |
| ZA (1) | ZA200203401B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20050114217A (en) * | 2003-02-21 | 2005-12-05 | 메드벳 싸이언스 피티와이. 리미티드 | A method of diagnosis and treatment |
| WO2009015263A2 (en) * | 2007-07-25 | 2009-01-29 | Wyeth | Methods for characterizing cell proximity |
| EP2467499A1 (en) * | 2009-08-21 | 2012-06-27 | Oncotherapy Science, Inc. | Cstf2 for target genes of lung cancer therapy and diagnosis |
| US11551360B2 (en) | 2020-04-28 | 2023-01-10 | QATAR UNIVERSITY, Office of Academic Research | Device and method for cancer detection |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5264343A (en) * | 1990-08-31 | 1993-11-23 | Eleanor Roosevelt Institute | Method for distinguishing normal and cancer cells |
| US5599919A (en) * | 1994-12-09 | 1997-02-04 | Fox Chase Cancer Center | Nucleic acid encoding a transiently-expressed kinetochore protein, and methods of use |
| US5891857A (en) * | 1996-02-20 | 1999-04-06 | Vanderbilt University | Characterized BRCA1 and BRCA2 proteins and screening and therapeutic methods based on characterized BRCA1 and BRCA2 proteins |
-
2000
- 2000-11-01 EP EP00984990A patent/EP1226439A1/en not_active Withdrawn
- 2000-11-01 NZ NZ519065A patent/NZ519065A/en unknown
- 2000-11-01 AU AU21565/01A patent/AU2156501A/en not_active Abandoned
- 2000-11-01 WO PCT/EP2000/011050 patent/WO2001033229A1/en not_active Application Discontinuation
- 2000-11-01 HU HU0203269A patent/HUP0203269A2/en unknown
- 2000-11-01 CA CA002389364A patent/CA2389364A1/en not_active Abandoned
- 2000-11-01 JP JP2001535063A patent/JP2003513282A/en active Pending
-
2002
- 2002-04-29 ZA ZA200203401A patent/ZA200203401B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1226439A1 (en) | 2002-07-31 |
| WO2001033229A1 (en) | 2001-05-10 |
| ZA200203401B (en) | 2003-04-29 |
| CA2389364A1 (en) | 2001-05-10 |
| NZ519065A (en) | 2004-03-26 |
| AU2156501A (en) | 2001-05-14 |
| JP2003513282A (en) | 2003-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Stark et al. | Whole-exome sequencing of acquired nevi identifies mechanisms for development and maintenance of benign neoplasms | |
| AU2849300A (en) | Methods and assay kits for detecting mononuclear cell phenotype | |
| Su et al. | Molecular characteristics and clinical outcomes of EGFR exon 19 indel subtypes to EGFR TKIs in NSCLC patients | |
| DE69938623D1 (en) | MICROARRAYS AND ITS USES | |
| ATE357663T1 (en) | ANALYTICAL TASSAY USING PARTICLE MARKER | |
| AU9198298A (en) | Polymorphism detection utilizing clustering analysis | |
| EP1415152A4 (en) | Methods, apparatus, and computer programs for verifying the integrity of a probe | |
| HUP0303888A2 (en) | Expression analysis of fkbp nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer | |
| WO2002000933A3 (en) | Screening assays for identifying modulators of the inflammatory or immune responses | |
| Brentnall et al. | Proteins that underlie neoplastic progression of ulcerative colitis | |
| FI946127A0 (en) | Method for extending the primer by one nucleotide to detect specific alleles, and a test kit for performing these methods | |
| Das et al. | Relevance of polyclonal plasma cells and post‐therapy immunomodulation in measurable residual disease assessment in multiple myeloma | |
| AU1259801A (en) | Detection method by pcr | |
| WO2007056332A3 (en) | Molecular diagnosis of autoimmune diseases | |
| Talla et al. | Immuno‐oncology gene expression profiling of formalin‐fixed and paraffin‐embedded clear cell renal cell carcinoma: Performance comparison of the NanoString nCounter technology with targeted RNA sequencing | |
| HUP0203269A2 (en) | Method for the detection of mammalian carcinomas | |
| CA2586654A1 (en) | Use of asc as a marker for colorectal cancer | |
| ATE449868T1 (en) | METHODS, TEST SETS AND COMPOSITIONS FOR DETECTING AND QUANTIFYING TARGET SEQUENCES | |
| ATE139803T1 (en) | ALLELIC ASSOCIATION OF THE HUMAN DOPAMINE (D2) RECEPTOR GENE IN COMPULSIVE DISORDERS SUCH AS ALCOHOLISM | |
| HUP0303890A2 (en) | Expression amalysis of inhibitor of differentiation nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer | |
| Goldeck et al. | Multi‐parametric phospho‐flow cytometry: A crucial tool for T lymphocyte signaling studies | |
| Köbel et al. | You won't believe this old test… that does cheap single‐cell mutation detection | |
| WO2004024949A3 (en) | Method of rapid detection of mutations and nucleotide polymorphisms using chemometrics | |
| CA2798441A1 (en) | Methods for predicting sensitivity to treatment with a targeted tyrosine kinase inhibitor | |
| Rai et al. | Utility of CD229 as novel marker in measurable residual disease assessment in multiple myeloma—An evidence‐based approach |